Oxytetracycline uterus injectant and preparation method thereof

A technology of oxytetracycline and injection, which is applied in the field of oxytetracycline uterine injection and its preparation, can solve the problems of uncertain treatment effect, slow absorption of oxytetracycline tablets, poor economic benefits, etc., and shorten the interval between initial preparations , prevention and treatment of chronic endometritis, and the effect of improving conception rate

Active Publication Date: 2011-11-23
FOSHAN NANHAI EASTERN ALONG PHARMA CO LTD
View PDF2 Cites 8 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

At home and abroad, oxytetracycline raw materials, tablets and effervescent agents are used to treat endometritis, but oxytetracycline tablets are absorbed slowly, have low effective concentration in blood, and short action time; and the therapeutic effect is uncertain, high cost, and economical. The benefit is poor, which brings great obstacles to clinical drug use

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Oxytetracycline uterus injectant and preparation method thereof
  • Oxytetracycline uterus injectant and preparation method thereof
  • Oxytetracycline uterus injectant and preparation method thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0020] Embodiment 1: oxytetracycline uterine injection of the present invention

[0021] An oxytetracycline uterine injection, prepared from oxytetracycline as the main raw material, 1000mL contains oxytetracycline 110g, magnesium oxide 4g, α-pyrrolidone 350g, anhydrous sodium sulfite 4g, triethanolamine 1.2g, the balance is injection use water.

Embodiment 2

[0022] Embodiment 2: oxytetracycline uterine injection of the present invention

[0023] An oxytetracycline uterine injection, prepared from oxytetracycline as the main raw material, 1000mL contains oxytetracycline 100g, magnesium oxide 5g, α-pyrrolidone 300g, anhydrous sodium sulfite 3.4g, triethanolamine 1g, the balance is injection use water.

Embodiment 3

[0024] Embodiment 3: the preparation of oxytetracycline uterine injection of the present invention

[0025] Take oxytetracycline 90g, magnesium oxide 5g, α-pyrrolidone 250g, anhydrous sodium sulfite 3g, triethanolamine 0.8g, add water for injection to dissolve, stir evenly, dilute to 1000mL with water for injection, centrifuge at 10000rpm for 10min to collect the supernatant.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to the field of medicinal preparation, and discloses an oxytetracycline uterus injectant, a preparation method thereof and application thereof in preparation of medicament for treating cow endometritis. The oxytetracycline uterus injectant of the invention comprises, in per 1000mL, 90-110g of oxytetracycline, 4-5g of magnesium oxide, 250-350g of alpha-pyrrolidone, 3-4g of anhydrous sodium sulfite, 0.8-1.2g of triethanolamine and the balance of injection water. The oxytetracycline uterus injectant of the invention has stable property, substantial treatment effect on endometritis and no stimulation effect on endometrium, and is safe and without adverse reactions, so as to shorten time interval from delivery to first mating, increase a conception rate in an estrus, a conception rate at a first heat and a total conception rate, effectively control generation of chronic endometritis. In addition, an oxytetracycline residual amount in cow milk is low; milk abandon timeis short; and integral benefit is high.

Description

technical field [0001] The invention relates to the field of pharmaceutical preparations, in particular to an oxytetracycline uterine injection and a preparation method thereof. Background technique [0002] Endometritis is an acute inflammation of the endometrium. It is an inflammation of the uterine mucosa caused by the invasion of various pathogenic microorganisms such as Streptococcus, Escherichia coli and Staphylococcus into the uterus of cows. It is the main cause of infertility in cows. one of the reasons. Endometritis is a common disease of reproductive diseases in dairy cows. According to reports, 12.19% of dairy cows in the United States suffer from reproductive diseases every year, and the economic loss is nearly 250 million US dollars; about 95% of infertile cows reported in the UK are due to endometritis In my country, the prevalence of dairy cow endometritis is also quite high. Endometritis can cause the fertilized eggs of affected cattle to fail to implant or...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K9/08A61K31/65A61K47/22A61P15/00
Inventor 辜垂鹏
Owner FOSHAN NANHAI EASTERN ALONG PHARMA CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap